New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
10:16 EDTINFY, DVA, RIMM, EIX, TEVA, RDS.A, QLGC, OXY, MYGN, KNXA, JNS, SJM, HMA, ELX, CNK, CF, RATEOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Bankrate (RATE) downgraded to Hold from Buy at Canaccord... Bankrate (RATE) downgraded to Sector Perform from Outperform at RBC Capital... CF Industries (CF) downgraded to Neutral from Overweight at Piper Jaffray... Cinemark (CNK) downgraded to Neutral from Overweight at JPMorgan... Emulex (ELX) downgraded to Sell from Neutral at Goldman... Health Management (HMA) downgraded to Sell from Fair Value at CRT Capital... J.M. Smucker (SJM) downgraded to Equal Weight from Overweight at Stephens... Janus Capital (JNS) downgraded to Sell from Neutral at Goldman... Kenexa (KNXA) downgraded to Market Perform from Outperform at JMP Securities... Myriad Genetics (MYGN) downgraded to Neutral from Buy at Mizuho... Occidental Petroleum (OXY) downgraded to Hold from Buy at Deutsche Bank... QLogic (QLGC) downgraded to Sell from Neutral at Goldman... Regal Entertainment (RGC) downgraded to Neutral from Overweight at JPMorgan... Royal Dutch Shell (RDS.A) downgraded to Hold from Buy at Deutsche Bank... Teva (TEVA) downgraded to Neutral from Buy at UBS... Edison International (EIX) downgraded to Market Perform from Outperform at Bernstein... Research in Motion (RIMM) downgraded to Sell from Hold at Canaccord... DreamWorks (DWA) downgraded to Sell from Hold at Stifel Nicolaus... Infosys (INFY) downgraded to Neutral from Outperform at Cowen.
News For A;TEVA;EIX;RIMM;DVA;INFY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 13, 2014
12:01 EDTINFYOptions with decreasing implied volatility
Options with decreasing implied volatility: EXAS INFY YUM FDO HSY
10:26 EDTINFYHigh option volume stocks
Subscribe for More Information
10:08 EDTINFYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:51 EDTINFYInfosys upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
06:11 EDTINFYInfosys upgraded to Buy from Hold at Deutsche Bank
October 10, 2014
13:29 EDTINFYInfosys price target raised to $56-$58 from $52-$54 at Wells Fargo
Subscribe for More Information
11:18 EDTINFYOptions with decreasing implied volatility
Subscribe for More Information
08:32 EDTINFYInfosys reports Q2 EPS 89c, consensus 81c
Subscribe for More Information
05:40 EDTINFYInfosys board approves bonus issue of one share for every share held
Subscribe for More Information
05:36 EDTINFYInfosys maintains FY15 reveneue growth outlook 7%-9%
Subscribe for More Information
05:35 EDTINFYInfosys reports Q2 EPS 89c, consensus 81c
Reports Q2 revenue $2.2B, consensus $2.2B. Infosys and its subsidiaries added 49 clients and 14,255 employees during the quarter.
October 9, 2014
16:11 EDTTEVAAlexza reports 32,278 Adasuve units shipped to Teva in Q3
Subscribe for More Information
14:56 EDTINFYInfosys technical comments ahead of earnings
The shares have outperformed in the past three months, with a decidedly bullish trend. At the current price of $59.45 the stock is not terribly far from its 52-week high at $63.20. This would likely be a level to be tested on better than expected results. If the news is sufficiently positive, it could lead to an additional breakout above the high with resistance at $65.04. If the news disappoints significantly, there is only a moderate percentage of the float short so there would be less buy-to-cover benefit. Over the past three years the $60 area has been tough resistance and disappointing results have lead to significant drops from that level. On an increasing band of negative surprises, support below would be at $57, $55.17, and $51.43 on an extreme move. The 52-week low is at $50.06.
14:09 EDTINFYInfosys October 60 straddle priced for 6.1% move into Q2
October 8, 2014
08:05 EDTTEVATeva initiates NDA submission to FDA for CEP-33237
Teva Pharmaceutical announced the initiation of a rolling New Drug Application submission to the U.S. Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Teva’s proprietary technology providing potential abuse-deterrent properties CEP-33237 as allowed for fast track designated products. Teva expects to complete the NDA submission by the end of 2014. Teva also announced positive results from a nasal Human Abuse Liability study which supports the NDA. The nasal HAL study found that in nondependent, recreational opioid users, abuse potential for crushed intranasal CEP-33237 was significantly lower than intranasal immediate-release hydrocodone. Teva has now completed positive HAL studies in the two most common routes of hydrocodone abuse, oral and intranasal. CEP-33237 demonstrated a safety profile in the Phase III study that is consistent with the known safety profile of hydrocodone and other opioid analgesic therapies. Adverse events reported in 5% or more of hydrocodone-treated patients during either the titration or double-blind treatment periods included nausea, constipation, vomiting, headache, somnolence and dizziness.
06:47 EDTTEVALawmakers may push for new regulations on generic drug makers, NY Times says
After the prices of some generic drugs soared more than 1,000% over the last year, two influential members of Congress are probing the sector and threatening to look to impose new regulations on it, according to The New York Times. Generic drug makers include Teva (TEVA), Mylan (MYL), Actavis (ACT), and Lannett (LCI).Reference Link
October 7, 2014
10:37 EDTINFYInfosys downgraded to Neutral from Buy at Citigroup
Subscribe for More Information
October 6, 2014
11:58 EDTTEVATeva simplifaction plans expected but positive, says BMO Capital
Subscribe for More Information
08:32 EDTTEVATeva identifies 14 pipeline projects for discontinuation or divestment
Subscribe for More Information
08:32 EDTTEVATeva announces results of strategic review of core specialty therapeutic areas
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use